NCT04598061

IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants

IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants : RACHI_dex

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 210 (estimated)
• Sponsor: University Hospital, Montpellier · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

* Spinal anesthesia in newborns is one of " Gold standard " techniques in short subumbilical surgeries (less than 30 minutes) with advantage of avoiding the risks inherent to general anesthesia. * Spinal anesthesia of the newborn remains a complex technical procedure with a failure rate of up to 16%. The child's movements and certain degrees of discomfort may also interfere with the successful completion of the procedure. * The second major issue of spinal anesthesia is the limitation of the motor block duration and the need for general anesthesia to complete the surgery * Spinal anesthesia duration can be prolonged by the addition of differents adjuvant such as opioid or alpha 2 adrenergic agonist. * Since 2018, dexmedetomidine, an alpha 2 adrenergic agonist with sedative, analgesic and anxiolytic properties, is being used as a current and standard practice in our anesthesia department. Intravenous administrationis performed ten to twenty minutes before spinal anesthesia placement in all children weighing less than 7 kg undergoing an infra-umbilical surgery of expected duration of less than 1 hour. This strategy ensures the child's comfort and allows the procedure to be performed under optimal conditions for practitionner. * The objective of this study is to review our practices and to evaluate the impact of the use of dexmedetomidine during spinal anesthesia of newborns and infants.

Conditions

• Newborns
• Infant
• Spinal Anesthesia

Interventions

Type	Name	Description
DRUG	Dexmedetomidine IV	Dexmedetomidine IV

Timeline

• Start date: 2020-10-01
• Primary completion: 2023-10-01
• Completion: 2023-11-28
• First posted: 2020-10-22
• Last updated: 2020-10-22

Locations

1 site across 1 country: France